BioMarin: Genzyme virus problem won

iwyqaxewun.wordpress.com
Genzyme (NASDAQ: GENZ) found a virus strain and stoppedd production of two drugs atthe Mass., facility. The strain, Vesivirus 2117, apparentlgy does not cause human infection but interruptsx the growth of cells that are used to make Aldurazyme — a treatment for MPS I, a rare and fata l disease caused by an enzyme deficiency — was last fillesd at the Genzyme facility in September 2008, accordinyg to BioMarin (NASDAQ: BMRN). The companyg has about 10 months of vialedr inventoryon hand, it said, and uses a seconsd fill finish supplier. A third supplier is expectedd to be qualified laterthis year, BioMarin said.
BioMarijn makes the bulk material used in Aldurazyme at itsNovatlo facility. The Food and Drug Administration hadinspected Genzyme’s plant in Septembedr and October and reportedly was concerned about controls to protect against